Desrosiers M, Klossek J-M, Benninger M
McGill University, Universite de Montréal, Montréal, Québec, Canada.
Int J Clin Pract. 2006 Feb;60(2):190-200. doi: 10.1111/j.1742-1241.2006.00753.x.
Acute bacterial rhinosinusitis (ABRS), which manifests as an inflammation of at least one of the paranasal sinuses, is a major public health issue in developed countries. Diagnosis and treatment of ABRS can pose significant challenges in clinical practice, including difficulty in differentiation between viral and bacterial infection and a lack of simple, reliable and convenient methods for definitive diagnosis. Treatment choice is also a challenge because a decision is typically made empirically; therefore, the selection of therapy should be based on knowledge of local patterns of antimicrobial resistance, spectrum of activity against the most common ABRS pathogens (including those that are resistant to penicillins and macrolides) and pharmacodynamic potency. Current guidelines for diagnosis and treatment of ABRS in various countries share some similarities but also have important differences. Criteria for making the clinical diagnosis of sinusitis vary only slightly from country to country, while recommendations of therapy reflect the local impact of bacterial resistance.
急性细菌性鼻窦炎(ABRS)表现为至少一个鼻窦的炎症,是发达国家的一个主要公共卫生问题。ABRS的诊断和治疗在临床实践中可能带来重大挑战,包括难以区分病毒感染和细菌感染,以及缺乏简单、可靠且便捷的确诊方法。治疗选择也是一项挑战,因为通常是凭经验做出决定;因此,治疗方案的选择应基于对抗菌药物耐药性的局部模式、对最常见ABRS病原体(包括对青霉素和大环内酯类耐药的病原体)的活性谱以及药效学效力的了解。各国目前的ABRS诊断和治疗指南有一些相似之处,但也存在重要差异。各国鼻窦炎临床诊断标准略有不同,而治疗建议则反映了细菌耐药性的局部影响。